Shandong Sinobioway Biomedicine News

Unnamed Pharmaceuticals: Report for the first quarter of 2025

SZSIApr 28 12:00 ET · Announcements

Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Simply Wall StApr 26 20:05 ET

Adding insult to injury! The core subsidiary of Shandong Sinobioway Biomedicine has been halted from production, with a revenue share of 60% | Quick read announcement.

① A subsidiary of Shandong Sinobioway Biomedicine responsible for the production and sale of interferon products has been subjected to risk control measures that involve the suspension of production and sales due to failing the Pharmaceutical GMP compliance inspection. ② Previously, Shandong Sinobioway Biomedicine's interferon α2b spray was recalled from shelves due to inspection results indicating that its "biological activity does not meet regulations."

cls.cnApr 24 11:07 ET

Shandong Sinobioway Biomedicine: Summary of the 2024 Annual Report

SZSIApr 23 12:00 ET · Announcements

Shandong Sinobioway Biomedicine: 2024 Annual Report

SZSIApr 23 12:00 ET · Announcements

Shandong Sinobioway Biomedicine (SZSE:002581 Investor Three-year Losses Grow to 46% as the Stock Sheds CN¥369m This Past Week

Simply Wall StApr 2 20:41 ET

Shandong Sinobioway Biomedicine (002581.SZ): plans to sign a "Sales Contract" with Jiangsu Suhao.

On March 12, GLONGLY announced that Shandong Sinobioway Biomedicine (002581.SZ) announced that its wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd. (referred to as "Shandong Yandu") signed a "Sales Contract" with Jiangsu Suhao Innovation Technology Group Co., Ltd. (referred to as "Jiangsu Suhao") to procure the required supply liquid system, chromatographic system, fillers, and reaction bags for the production workshop of recombinant neurotrophic factor eye drops for the ShanDong Sinobioway Biomedical Industrial Park project.

Gelonghui FinanceMar 12 07:28 ET

Companies Like Shandong Sinobioway Biomedicine (SZSE:002581) Are In A Position To Invest In Growth

Simply Wall StFeb 24 18:02 ET

Unnamed Pharmaceuticals: 2024 Annual Results Forecast

SZSIJan 24 11:00 ET · Announcements

Sinobioway Biomedicine's Unit Signs 65 Million Yuan Construction Deal for Industrial Park

MT NewswiresJan 24 04:19 ET

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 27% Share Price Plunge Could Signal Some Risk

Simply Wall StJan 3 17:34 ET

Shandong Sinobioway Biomedicine (002581.SZ): plans to increase the capital of its wholly-owned subsidiary ShanDong YanDu by 0.29 billion yuan.

On January 3, Gelonghui reported that Shandong Sinobioway Biomedicine (002581.SZ) announced the company is using its own funds to increase capital by 0.29 billion yuan for its wholly-owned subsidiary ShanDong Yandu Biotechnology Co., Ltd. (referred to as "ShanDong Yandu"), of which 0.29 billion yuan will be included in registered capital and 0 yuan in capital surplus. After the capital increase, ShanDong Yandu's registered capital will reach 0.3 billion yuan, remaining a wholly-owned subsidiary of the company. Meanwhile, the Board of Directors has authorized the company's management to handle the specific procedures related to the capital increase.

Gelonghui FinanceJan 3 05:49 ET

Shandong Sinobioway Biomedicine (002581.SZ) subsidiary plans to hire Happy Life to provide clinical trial technical services.

Shandong Sinobioway Biomedicine (002581.SZ) announced that the company's Board of Directors has reviewed and approved the "Agreement on Signing the Technical..."

Zhitong FinanceJan 3 05:46 ET

Shandong Sinobioway Biomedicine (002581.SZ): Granted 19.6346 million stock Options to 100 incentive targets.

On December 23, Gelonghui reported that Shandong Sinobioway Biomedicine (002581.SZ) announced that the granting conditions stipulated in the "2024 Stock Options Incentive Plan (Draft) of Shandong Sinobioway Biomedicine Co., Ltd." have been met. According to the authorization of the fourth extraordinary Shareholders' Meeting of Shandong Sinobioway Biomedicine Co., Ltd. in 2024, the company held the 31st meeting of the 5th Board of Directors and the 21st meeting of the 5th Board of Supervisors on December 20, 2024, to review and approve the "Proposal on Granting Stock Options to the Incentive Objectives of the Company's 2024 Stock Options Incentive Plan," agreeing to use December 2024.

Gelonghui FinanceDec 23, 2024 05:02 ET

Despite Currently Being Unprofitable, Shandong Sinobioway Biomedicine (SZSE:002581) Has Delivered a 88% Return to Shareholders Over 5 Years

Simply Wall StDec 20, 2024 00:02 ET

Shandong Sinobioway Biomedicine (002581.SZ) has appointed Zhou Ting as the financial director.

Shandong Sinobioway Biomedicine (002581.SZ) announced that the company's board of directors recently received a report from the Chief Financial Officer, Mr. Liu Yangjun...

Zhitong FinanceDec 5, 2024 07:51 ET

Shandong Sinobioway Biomedicine (002581.SZ) plans to launch a stock options incentive plan for 2024, with an exercise price of 12.35 yuan per share.

Shandong Sinobioway Biomedicine (002581.SZ) has announced the 2024 stock options incentive plan (draft), which grants...

Zhitong FinanceDec 2, 2024 09:31 ET

We're Not Very Worried About Shandong Sinobioway Biomedicine's (SZSE:002581) Cash Burn Rate

Simply Wall StNov 14, 2024 18:12 ET

Unnamed Pharmaceuticals: Report for the third quarter of 2024

SZSIOct 29, 2024 12:00 ET · Announcements

Shandong Sinobioway Biomedicine (002581.SZ): The net income in the first three quarters was 14.6263 million yuan, a year-on-year decrease of 50.78%.

Glory Run on October 29丨Shandong Sinobioway Biomedicine (002581.SZ) announced its third quarter report for 2024, with the company achieving revenue of 0.315 billion yuan in the first three quarters, a 6.99% year-on-year decrease; net income attributable to shareholders of the listed company was 14.6263 million yuan, a 50.78% year-on-year decrease; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 16.5706 million yuan, a 49.02% year-on-year decrease; and basic earnings per share was 0.0222 yuan.

Gelonghui FinanceOct 29, 2024 08:27 ET